A carregar...
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data
Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excre...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4058745/ https://ncbi.nlm.nih.gov/pubmed/24936262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i3.399 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|